Get the Stockscreener App
68.26
1.62%
1.09
Hologic Inc stock is traded at $68.26, with a volume of 1.55M.
It is up +1.62% in the last 24 hours and up +4.42% over the past month.
Hologic manufactures proprietary products for the healthcare needs of women. The company operates in four segments: diagnostics (44% of total sales), breast health (38%), surgical (16%), and skeletal health (2%). While the company traditionally focused on breast health, the acquisition of Gen-Probe put greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (69%), followed by Europe (20%), Asia (8%), and other international markets (3%). Hologic is headquartered in Bedford, Massachusetts.
See More
Previous Close:
$67.17
Open:
$67.7
24h Volume:
1.55M
Relative Volume:
0.61
Market Cap:
$15.18B
Revenue:
$4.03B
Net Income/Loss:
$556.70M
P/E Ratio:
28.80
EPS:
2.37
Net Cash Flow:
$970.10M
1W Performance:
+0.66%
1M Performance:
+4.42%
6M Performance:
+5.85%
1Y Performance:
-14.77%
1-Day Range:
$66.67
$68.47
1-Week Range:
$66.67
$69.03
52-Week Range:
$51.90
$84.39
Hologic Inc Stock (HOLX) Company Profile
Name
Hologic Inc
Sector
Industry
Phone
(508) 263-2900
Address
250 CAMPUS DRIVE, MARLBOROUGH, MA
Compare HOLX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HOLX
Hologic Inc
|
68.26 | 14.96B | 4.03B | 556.70M | 970.10M | 2.37 |
|
ISRG
Intuitive Surgical Inc
|
476.16 | 172.53B | 9.15B | 2.63B | 1.99B | 7.17 |
|
BDX
Becton Dickinson Co
|
199.66 | 55.89B | 21.39B | 1.61B | 2.55B | 5.56 |
|
ALC
Alcon Inc
|
82.02 | 43.59B | 9.93B | 1.12B | 1.43B | 2.26 |
|
RMD
Resmed Inc
|
293.73 | 41.89B | 5.15B | 1.40B | 1.65B | 9.51 |
|
WST
West Pharmaceutical Services Inc
|
247.85 | 17.48B | 2.96B | 487.70M | 344.00M | 6.68 |
Hologic Inc Stock (HOLX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-06-25 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Jul-09-25 | Upgrade | Citigroup | Neutral → Buy |
| May-27-25 | Reiterated | Needham | Hold |
| Mar-03-25 | Downgrade | Argus | Buy → Hold |
| Feb-06-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Feb-03-25 | Downgrade | Needham | Buy → Hold |
| Dec-13-24 | Initiated | Wolfe Research | Peer Perform |
| Dec-10-24 | Initiated | Jefferies | Hold |
| Dec-10-24 | Reiterated | Needham | Buy |
| Oct-01-24 | Downgrade | Citigroup | Buy → Neutral |
| Jun-27-24 | Initiated | Stephens | Overweight |
| Apr-03-24 | Upgrade | Citigroup | Neutral → Buy |
| Jul-14-23 | Upgrade | Needham | Hold → Buy |
| Dec-07-22 | Initiated | RBC Capital Mkts | Sector Perform |
| Oct-13-22 | Initiated | Mizuho | Buy |
| Jul-20-22 | Downgrade | BofA Securities | Buy → Neutral |
| Jul-20-22 | Initiated | UBS | Neutral |
| Jul-18-22 | Downgrade | BTIG Research | Buy → Neutral |
| Apr-25-22 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-04-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Dec-15-21 | Downgrade | Citigroup | Buy → Neutral |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Oct-14-21 | Initiated | Redburn | Neutral |
| Jul-06-21 | Upgrade | Evercore ISI | In-line → Outperform |
| Nov-20-20 | Downgrade | Needham | Buy → Hold |
| Nov-05-20 | Reiterated | Needham | Buy |
| Jun-30-20 | Upgrade | Cowen | Market Perform → Outperform |
| Jun-03-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Apr-30-20 | Reiterated | Needham | Buy |
| Apr-30-20 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Apr-07-20 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-27-20 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Jan-13-20 | Reiterated | Needham | Buy |
| Jan-08-20 | Initiated | Wells Fargo | Equal Weight |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Jan-02-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Sep-26-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Aug-01-19 | Reiterated | Needham | Buy |
| May-02-19 | Reiterated | Needham | Buy |
| Jan-31-19 | Reiterated | Needham | Buy |
| Jan-02-19 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Oct-09-18 | Initiated | UBS | Neutral |
| Sep-13-18 | Downgrade | BofA/Merrill | Buy → Neutral |
View All
Hologic Inc Stock (HOLX) Latest News
Hologic Inc. stock outperforms competitors on strong trading day - MarketWatch
What's Behind Hologic's Positive Long-Term Outlook For Cytology Unit? - Barchart.com
Here's Why Hologic (HOLX) is a Strong Value Stock - Yahoo Finance
What's Behind Hologic's Positive Long-Term Outlook for Cytology Unit? - Nasdaq
Stock Analysis | Hologic OutlookMixed Signals Amid Strong Fundamentals and Divergent Analyst Views - AInvest
Hologic Inc. Approaches Support With Recovery in Sight2025 Key Highlights & Reliable Trade Execution Plans - classian.co.kr
Argus Upgrades Hologic to Buy From Hold, Price Target is $80 - MarketScreener
Will Hologic Inc. benefit from current market trendsPortfolio Risk Summary & AI Powered Market Entry Strategies - sundaytimes.kr
What to Expect From Hologic's Q3 2025 Earnings Report - MSN
Does Hologic Inc. have high return on assets2025 Short Interest & Weekly High Potential Stock Alerts - classian.co.kr
Saliva-based Screening Market CAGR 7.70% Trends with Thermo - openPR.com
Hologic Reports Strong Q3 2025 Earnings, Exceeds Guidance - MSN
Stephens Adjusts Price Target on Hologic to $78 From $70 - MarketScreener
Is Trending Stock Hologic, Inc. (HOLX) a Buy Now? - Yahoo Finance
Hologic Eyes Organic Growth Rebound in 2026 on Breast Health Strength - MSN
Hologic Management to Meet Virtually with BTIG on August 21 - AInvest
Hologic's Growth Prospects and Undervalued Stock Support Buy Rating - AInvest
Hologic Stock Performance: Underperforms Market Despite Quarterly GainsNews and Statistics - IndexBox
What Are Wall Street Analysts' Target Price for Hologic Stock? - Yahoo Finance
Hologic Stock Target Price: A Closer Look - AInvest
What Are Wall Street Analysts' Target Price For Hologic Stock? - Barchart.com
Body Fat Measurement Market to Witness Growth and Comprehensive - openPR.com
Hologic’s Q2 Earnings Call: Our Top 5 Analyst Questions - Yahoo Finance
HOLX Q2 Deep Dive: Breast Health Turnaround and New Product Launches Drive Momentum - FinancialContent
STD Diagnostic Market Forecast and Company Analysis Report - GlobeNewswire
STD Diagnostic Market Forecast and Company Analysis Report 2025-2033 Featuring Siemens, Abbott, MedMira, QIAGEN, Danaher, F. Hoffmann-La Roche, Diasorin, BioMeriuex, Hologic, Bio-Rad Laboratories - Yahoo Finance
Hologic's Diagnostics Arm Set for Long-Term Upside: What's Behind It? - MSN
Hologic's Diagnostics Arm Set For Long-Term Upside: What's Behind It? - Barchart.com
There May Be Some Bright Spots In Hologic's (NASDAQ:HOLX) Earnings - Yahoo Finance
RadNet hires Hologic, Bausch + Lomb alum Jane Mazur - Medical Marketing and Media
Hologic’s Growth Story Looks Set For A Comeback - Finimize
RBC Capital Reiterates Buy Rating for Hologic with $87 Price Target - AInvest
RBC Capital Upgrades Hologic (HOLX) to Outperform with Raised Pr - GuruFocus
Forecasting the Future: Next-Generation Biopsy-Based Cancer - openPR.com
Should You Buy, Sell or Hold Hologic Stock Post Q3 Earnings? - The Globe and Mail
Should You Buy, Sell Or Hold Hologic Stock Post Q3 Earnings? - Barchart.com
Hpv And Pap Testing Market Generated Opportunities, Future - openPR.com
RBC Capital Upgrades Hologic to Outperform From Sector Perform, Adjusts PT to $87 From $72 - MarketScreener
RBC Capital upgrades Hologic stock to Outperform on expected growth By Investing.com - Investing.com Canada
RBC Capital upgrades Hologic stock to Outperform on expected growth - Investing.com
Molecular Diagnostics Market Expands with Infectious Disease - openPR.com
Hologic, Inc. (HOLX) is Attracting Investor Attention: Here is What You Should Know - MSN
Analysts Have Made A Financial Statement On Hologic, Inc.'s (NASDAQ:HOLX) Third-Quarter Report - simplywall.st
Why Hologic (HOLX) is a Top Value Stock for the Long-Term - Yahoo Finance
Hologic Inc Stock (HOLX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Hologic Inc Stock (HOLX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Mitchell Essex D | Chief Operating Officer |
Dec 04 '24 |
Option Exercise |
62.60 |
22,902 |
1,433,659 |
52,813 |
| Mitchell Essex D | Chief Operating Officer |
Dec 04 '24 |
Sale |
76.34 |
24,856 |
1,897,482 |
27,957 |
2.98%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):